Revenue (Tables)

3 Months Ended

Jan. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

	Three Months Ended January 31,
	2020								2019
	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total		Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Revenue by Region
Americas	$	209	$	118	$	167	$	494	$	168	$	109	$	156	$	433
Europe	167		92		133		392		164		91		128		383
Asia Pacific	262		39		170		471		275		35		158		468
Total	$	638	$	249	$	470	$	1,357	$	607	$	235	$	442	$	1,284

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:

	Three Months Ended
	January 31,
	2020		2019
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical	$	423	$	391
Chemical and Energy	312		308
Diagnostics and Clinical	194		187
Food	130		129
Academia and Government	141		116
Environmental and Forensics	157		153
Total	$	1,357	$	1,284
Revenue by Type
Instrumentation	$	593	$	567
Non-instrumentation and other	764		717
Total	$	1,357	$	1,284

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2020:

	Contract Liabilities
	(in millions)
Ending balance as of October 31, 2019	$	386
Net revenue deferred in the period	180
Revenue recognized that was included in the contract liability balance at the beginning of the period	(142		)
Change in deferrals from customer cash advances, net of revenue recognized	9
Currency translation and other adjustments	(1		)
Ending balance as of January 31, 2020	$	432